New PNH drug VSA012 enters early human testing
Disease control
Ongoing
This early-stage trial tests a new drug called VSA012 in about 50 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that destroys red blood cells. The study includes people who have not used complement inhibitors before or who still have low hemoglobin …
Phase: PHASE1 • Sponsor: Bisirna Therapeutics Pte. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC